Pediatric OTC study shows caregiver confusion
This article was originally published in The Tan Sheet
Executive Summary
Parents reading the front label of OTC pediatric cough/cold products overwhelmingly believe them safe for children younger than 2 years, despite language advising consultation with a doctor before administering to that age group, a study says. The report on parental misinterpretations of cough/cold drug labels, published in the June Pediatrics journal, concludes the word "infant" and graphics such as teddy bears on labels led 86 percent of the 182 recruited caregivers to say they would give the products to children younger than 2 years. After viewing an entire product package, 51 percent said they would administer the drugs to a 13-month-old, said researchers led by Russell Rothman of Vanderbilt University Medical Center. Heinz Schneider, VP of science & medical affairs for the Consumer Healthcare Products Association, noted in a May 26 statement the study created an "artificial scenario" using pediatric products that have since been withdrawn from the market in the wake of safety and efficacy concerns about pediatric cough/cold drugs (1"The Tan Sheet" Oct. 13, 2009, p. 4)
You may also be interested in...
Firms Consult FDA, Add “Do Not Use” For Under 4 To Pediatric Cold Products
Over-the-counter pediatric cough/cold products relabeled "do not use" for children under 4 will reach shelves in the next few weeks in a voluntary program manufacturers coordinated with FDA
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.